Wayne Weisman - 15 Jun 2022 Form 4 Insider Report for Baudax Bio, Inc. (BXRX)

Role: Director
Signature: /s/ Jillian Dilmore, Attorney-in-fact
Issuer symbol: BXRX
Transactions as of: 15 Jun 2022
Transactions value $: $0
Form type: 4
Filing time: 17 Jun 2022, 16:10:12 UTC
Previous filing: 20 May 2022
Next filing: 03 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BXRX	Common Stock	Award	$0	+39.5K	+1151.82%	$0.00	42.9K	15 Jun 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.

Content

Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.